This article is more than 5 years old. Information may no longer be current.
Cardiology Today's Intervention top articles in May
Click Here to Manage Email Alerts
Cardiology Today’s Intervention compiled a list of the top 5 stories posted to Healio.com/Intervention in May.
This month, Cardiology Today’s Intervention readers were most interested in benefits of adventitial drug delivery for patients with peripheral artery disease, the results of the DAWN and ACIST-FFR trials, coronary angiography after high-risk non-STEMI, the results of the REPRISE-III study, and much more.
Adventitial drug delivery yields benefit in PAD
NEW ORLEANS — Localized delivery of dexamethasone into the adventitia via a novel micro-infusion device resulted in significant reductions in inflammatory biomarkers, which may provide a new strategy for outcome prediction and personalized therapy for patients with PAD.
DAWN: Endovascular therapy beneficial beyond 6 hours after acute ischemic stroke
Results of the DAWN trial, presented at the European Stroke Organization Conference, show that endovascular therapy to remove a stroke-causing blood clot in the brain was superior to medical therapy alone even when the procedure was performed between 6 and 24 hours after stroke.
ACIST-FFR: Microcatheter FFR produces similar results to standard system
A microcatheter fractional flow reserve system demonstrated similar results to standard pressure wire systems for assessment of lesion characteristics in patients with stable CAD, according to results presented at EuroPCR.
VIDEO: Early intervention might provide clinical benefit in patients with high-risk non-STEMI
NEW ORLEANS — Emmanouil S. Brilakis, MD, PhD, director of the center for advanced coronary interventions at the Minneapolis Heart Institute, and a Cardiology Today’s Intervention editorial board member, spoke with Cardiology Today’s Intervention about the results of a study that demonstrated that the earlier a patient underwent coronary angiography after presenting to the hospital with high-risk non-STEMI, the more likely the patient was to have better outcomes with less adverse events.
TAVR system with repositionable valve safe, effective vs. self-expanding valve
A transcatheter aortic valve replacement system with a repositionable valve was similar in safety and superior in efficacy to a self-expanding system, according to findings from the REPRISE III trial presented at EuroPCR.